RxDoctor Payments Data

Ada Sanchez-Juan

Optometrist · Lexington, KYNPI 1861982241

Payments from drug & device makers

$2,291in general payments, 2019–2025

Across 113 payments — averaging $20.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$734
  • Sun Pharmaceutical Industries Inc.$375
  • Bausch & Lomb Americas Inc.$346
  • Coopervision Inc.$205
  • Oyster Point Pharma, Inc.$162
  • Alcon$156
  • plus $314 from 6 others

What the payments were for

  • Food & beverage$2,25198%
  • Education$402%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,291 in reported general payments places this provider in the 75th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$65,093
Medicare patients
361
Services billed
732

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine118$180,917
LumiganBimatoprost141$74,728
XiidraLifitegrast64$72,025
CequaCyclosporine30$26,741
XdemvyLotilaner13$23,996
Cyclosporine15$15,720
RocklatanNetarsudil Mesylat/Latanoprost18$10,418
VyzultaLatanoprostene Bunod18$8,371
CombiganBrimonidine Tartrate/Timolol12$8,258
Brimonidine Tartrate35$3,990
Cosopt PfDorzolamide/Timolol/Pf15$2,962
Latanoprost157$2,243
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat105$2,082
Travoprost15$1,314
Prednisolone Acetate11$422

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$734$263,903271 claims
Bausch & Lomb Americas Inc.Xiidra, Vyzulta$346$80,39682 claims
Sun Pharmaceutical Industries Inc.Cequa$375$26,74130 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →